Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial

Objective. 1,25-Dihydroxyvitamin D (1,25([OH]2D) is considered to be a negative endogenous regulator of the renin-angiotensin-aldosterone system (RAAS), but the effect of vitamin D supplementation on the RAAS is inconclusive. Design. In this prespecified secondary analysis of a randomized controlled...

Full description

Saved in:
Bibliographic Details
Main Authors: Armin Zittermann, Jana B. Ernst, Sylvana Prokop, Uwe Fuchs, Jens Dreier, Joachim Kuhn, Cornelius Knabbe, Jochen Börgermann, Heiner K. Berthold, Stefan Pilz, Ioanna Gouni-Berthold, Jan F. Gummert
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2018/5015417
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850161587286966272
author Armin Zittermann
Jana B. Ernst
Sylvana Prokop
Uwe Fuchs
Jens Dreier
Joachim Kuhn
Cornelius Knabbe
Jochen Börgermann
Heiner K. Berthold
Stefan Pilz
Ioanna Gouni-Berthold
Jan F. Gummert
author_facet Armin Zittermann
Jana B. Ernst
Sylvana Prokop
Uwe Fuchs
Jens Dreier
Joachim Kuhn
Cornelius Knabbe
Jochen Börgermann
Heiner K. Berthold
Stefan Pilz
Ioanna Gouni-Berthold
Jan F. Gummert
author_sort Armin Zittermann
collection DOAJ
description Objective. 1,25-Dihydroxyvitamin D (1,25([OH]2D) is considered to be a negative endogenous regulator of the renin-angiotensin-aldosterone system (RAAS), but the effect of vitamin D supplementation on the RAAS is inconclusive. Design. In this prespecified secondary analysis of a randomized controlled trial, we assessed in 165 patients with heart failure (vitamin D group: n=83; placebo group: n=82) the effect of three years of vitamin D supplementation with 4000 IU daily on parameters of the RAAS (renin and aldosterone) and on circulating 1,25(OH)2D, plasma phosphate, and fibroblast growth factor (FGF)-23. We assessed age- and baseline-adjusted between-group differences at study termination. Results. Almost all patients were under treatment with beta-blockers, inhibitors of the RAAS, and diuretics. Initially, the frequency of concentrations above the laboratory-specific reference range (renin: >23.9 mIU/L; aldosterone: >232 ng/L) in the vitamin D and placebo group was 87.7% and 92.7%, respectively (renin), and 24.1% and 32.5%, respectively (aldosterone). Vitamin D increased adjusted 1,25(OH)2D concentrations significantly (mean treatment effect and 95% CI: 18.3 pmol/L,7.3 to 29.3 pmol/L; P<0.001) but had no significant effects on phosphate (0.18 mmol/L, −0.00 to 0.35 mmol/L; P=0.051), FGF-23 (685 RU/mL, −213 to 1585 RU/mL; P=0.134), renin (312 mIU/L, −279 to 902 ng/L; P=0.298), or aldosterone (−0.19 ng/L, −5.09 to 4.70 ng/L; P=0.938). Vitamin D supplementation was, however, associated with an increase in renin concentrations in the subgroup with baseline 25-hydroxyvitamin D below 30 nmol/L (n=67; 1365 mIU/, 343 to 2386 mIU/L; P=0.010). Conclusions. In patients with advanced heart failure treated according to evidence-based guidelines, vitamin D supplementation did not significantly influence parameters of the RAAS in the entire study cohort but was associated with an increase in plasma renin concentrations in the subgroup with low baseline 25-hydroxyvitamin D concentrations.
format Article
id doaj-art-f75d4f77b48a4dd7be83d3a01d200ae6
institution OA Journals
issn 1687-8337
1687-8345
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-f75d4f77b48a4dd7be83d3a01d200ae62025-08-20T02:22:46ZengWileyInternational Journal of Endocrinology1687-83371687-83452018-01-01201810.1155/2018/50154175015417Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA TrialArmin Zittermann0Jana B. Ernst1Sylvana Prokop2Uwe Fuchs3Jens Dreier4Joachim Kuhn5Cornelius Knabbe6Jochen Börgermann7Heiner K. Berthold8Stefan Pilz9Ioanna Gouni-Berthold10Jan F. Gummert11Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, 32545 Bad Oeynhausen, GermanyClinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, 32545 Bad Oeynhausen, GermanyClinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, 32545 Bad Oeynhausen, GermanyClinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, 32545 Bad Oeynhausen, GermanyInstitute for Laboratory and Transfusion Medicine, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, 32545 Bad Oeynhausen, GermanyInstitute for Laboratory and Transfusion Medicine, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, 32545 Bad Oeynhausen, GermanyInstitute for Laboratory and Transfusion Medicine, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, 32545 Bad Oeynhausen, GermanyClinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, 32545 Bad Oeynhausen, GermanyDepartment of Internal Medicine and Geriatrics, Bethel Clinic (EvKB), 33611 Bielefeld, GermanyPolyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, 50937 Cologne, GermanyDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, AustriaClinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Ruhr University Bochum, 32545 Bad Oeynhausen, GermanyObjective. 1,25-Dihydroxyvitamin D (1,25([OH]2D) is considered to be a negative endogenous regulator of the renin-angiotensin-aldosterone system (RAAS), but the effect of vitamin D supplementation on the RAAS is inconclusive. Design. In this prespecified secondary analysis of a randomized controlled trial, we assessed in 165 patients with heart failure (vitamin D group: n=83; placebo group: n=82) the effect of three years of vitamin D supplementation with 4000 IU daily on parameters of the RAAS (renin and aldosterone) and on circulating 1,25(OH)2D, plasma phosphate, and fibroblast growth factor (FGF)-23. We assessed age- and baseline-adjusted between-group differences at study termination. Results. Almost all patients were under treatment with beta-blockers, inhibitors of the RAAS, and diuretics. Initially, the frequency of concentrations above the laboratory-specific reference range (renin: >23.9 mIU/L; aldosterone: >232 ng/L) in the vitamin D and placebo group was 87.7% and 92.7%, respectively (renin), and 24.1% and 32.5%, respectively (aldosterone). Vitamin D increased adjusted 1,25(OH)2D concentrations significantly (mean treatment effect and 95% CI: 18.3 pmol/L,7.3 to 29.3 pmol/L; P<0.001) but had no significant effects on phosphate (0.18 mmol/L, −0.00 to 0.35 mmol/L; P=0.051), FGF-23 (685 RU/mL, −213 to 1585 RU/mL; P=0.134), renin (312 mIU/L, −279 to 902 ng/L; P=0.298), or aldosterone (−0.19 ng/L, −5.09 to 4.70 ng/L; P=0.938). Vitamin D supplementation was, however, associated with an increase in renin concentrations in the subgroup with baseline 25-hydroxyvitamin D below 30 nmol/L (n=67; 1365 mIU/, 343 to 2386 mIU/L; P=0.010). Conclusions. In patients with advanced heart failure treated according to evidence-based guidelines, vitamin D supplementation did not significantly influence parameters of the RAAS in the entire study cohort but was associated with an increase in plasma renin concentrations in the subgroup with low baseline 25-hydroxyvitamin D concentrations.http://dx.doi.org/10.1155/2018/5015417
spellingShingle Armin Zittermann
Jana B. Ernst
Sylvana Prokop
Uwe Fuchs
Jens Dreier
Joachim Kuhn
Cornelius Knabbe
Jochen Börgermann
Heiner K. Berthold
Stefan Pilz
Ioanna Gouni-Berthold
Jan F. Gummert
Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial
International Journal of Endocrinology
title Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial
title_full Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial
title_fullStr Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial
title_full_unstemmed Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial
title_short Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial
title_sort effects of vitamin d supplementation on renin and aldosterone concentrations in patients with advanced heart failure the evita trial
url http://dx.doi.org/10.1155/2018/5015417
work_keys_str_mv AT arminzittermann effectsofvitamindsupplementationonreninandaldosteroneconcentrationsinpatientswithadvancedheartfailuretheevitatrial
AT janabernst effectsofvitamindsupplementationonreninandaldosteroneconcentrationsinpatientswithadvancedheartfailuretheevitatrial
AT sylvanaprokop effectsofvitamindsupplementationonreninandaldosteroneconcentrationsinpatientswithadvancedheartfailuretheevitatrial
AT uwefuchs effectsofvitamindsupplementationonreninandaldosteroneconcentrationsinpatientswithadvancedheartfailuretheevitatrial
AT jensdreier effectsofvitamindsupplementationonreninandaldosteroneconcentrationsinpatientswithadvancedheartfailuretheevitatrial
AT joachimkuhn effectsofvitamindsupplementationonreninandaldosteroneconcentrationsinpatientswithadvancedheartfailuretheevitatrial
AT corneliusknabbe effectsofvitamindsupplementationonreninandaldosteroneconcentrationsinpatientswithadvancedheartfailuretheevitatrial
AT jochenborgermann effectsofvitamindsupplementationonreninandaldosteroneconcentrationsinpatientswithadvancedheartfailuretheevitatrial
AT heinerkberthold effectsofvitamindsupplementationonreninandaldosteroneconcentrationsinpatientswithadvancedheartfailuretheevitatrial
AT stefanpilz effectsofvitamindsupplementationonreninandaldosteroneconcentrationsinpatientswithadvancedheartfailuretheevitatrial
AT ioannagouniberthold effectsofvitamindsupplementationonreninandaldosteroneconcentrationsinpatientswithadvancedheartfailuretheevitatrial
AT janfgummert effectsofvitamindsupplementationonreninandaldosteroneconcentrationsinpatientswithadvancedheartfailuretheevitatrial